Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2025
vol. 76
 
Share:
Send email
Share:
Original paper

Does loss of ARID1A expression affect neoadjuvant chemoradiotherapy response in rectal carcinomas?

Nagehan O. Barisik
1
,
Sibel Sensu
2
,
Sevinc H. Keser
1
,
Yesim S. Gurbuz
2
,
Ozgul Ozdemir
3
,
Ramazan O. Yuceer
4
,
AylinE. Gul
1
,
Nusret Erdogan
2

  1. Department of Pathology, Kartal Dr. Lutfi Kirdar City Hospital, University of Health Sciences, Istanbul, Turkey
  2. Department of Pathology, Medical Faculty, Istinye University, Istanbul, Turkey
  3. Pathology Clinic, Midyat State Hospital, Mardin, Turkey
  4. Pathology Clinic, Batman Training and Research Hospital, Batman, Turkey
Pol J Pathol 2025; 76 (2): 87-93
DOI: https://doi.org/10.5114/pjp.2025.153970
Online publish date: 2025/09/22
Article file
- PJP-03292.pdf  [0.32 MB]
Get citation
 
PlumX metrics:
 
1. Conces ML, Mahipal A. Adoption of Total Neoadjuvant Ther­apy in the Treatment of Locally Advanced Rectal Cancer. Curr Oncol 2024; 31: 366-382.
2. Feeney G, Sehgal R, Sheehan M, et al. Neoadjuvant radio­therapy for rectal cancer management. World J Gastroenterol 2019; 25: 4850-4869.
3. Mullen J, Kato S, Sicklick JK, Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev 2021; 100: 102287.
4. Xu S, Tang C. The Role of ARID1A in Tumors: Tumor Initia­tion or Tumor Suppression? Front Oncol 2021; 11: 745187.
5. Peerapen P, Sueksakit K, Boonmark W, Yoodee S, Thong­boonkerd V. ARID1A knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An in vitro cellular mechanism study. J Cancer 2022; 13: 373-384.
6. Pavlidou EN, Balis V. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes. World Acad Sci J 2020; 2: 49-64.
7. Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle 2016; 15: 196-212.
8. Kim SM, Yoon G, Seo AN. What are the most important prog­nostic factors in patients with residual rectal cancer after preop­erative chemoradiotherapy? Yeungnam Univ J Med 2019; 36: 124-135.
9. Kolorektal Kanser Klinik Protokolü. Versiyon 1.0. T.C. Sag­lik Bakanligi Saglik Hizmetleri Genel Müdürlügü Saglik Teknolojisi Degerlendirme Daire Baskanligi. Available at: https://dosyamerkez.saglik.gov.tr/Eklenti/36748/0/kolorek­talkanserklinikprotokolu20200227pdf.pdf?_tag1=8D74759 E718E04C56EECD2BD5363253461F6B7E3.
10. Ryan R, Gibbons D, Hyland JM, et al. The pathological re­sponse following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005; 47: 141-146.
11. Sun D, Zhu, Y, Zhao H, et al. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis. Cell Oncol 2021; 44: 1019-1034.
12. Wang T, Guo J, Liu W, et al. Downregulation of ARID1A is correlated with poor prognosis in non-small cell lung cancer. Transl Cancer Res 2020; 9: 4896-4905.
13. Katz M, Amit I, Citri A, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007; 9: 961-969.
14. Chen K, Collins G, Wang H, Toh JWT. Pathological Features and Prognostication in Colorectal Cancer. Curr Oncol 2021; 28: 5356-5383.
15. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guide­lines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw 2020; 18: 806-815.
16. Deschner BW, VanderWalde NA, Grothey A, Shibata D. Evo­lution and Current Status of the Multidisciplinary Manage­ment of Locally Advanced Rectal Cancer. JCO Oncol Pract 2021; 17: 383-402.
17. Leeds IL, Fang SH. Neoadjuvant Therapy for Rectal Cancer. Dis Colon Rectum 2018; 61: 883-886.
18. Wei XL, Wang DS, Xi SY, et al. Clinicopathologic and prog­nostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol 2014; 20: 18404-18412.
19. https://documents.cap.org/protocols/cp-gilower-colonrectum- 17protocol-4010.pdf.
20. Chen HY, Feng LL, Li M, et al. College of American Patholo­gists Tumor Regression Grading System for Long-Term Out­come in Patients with Locally Advanced Rectal Cancer. Oncol­ogist 2021; 26: e780-e793.
21. Tong Y, Liu D, Zhang J. Connection and distinction of tumor regression grading systems of gastrointestinal cancer. Pathol Res Pract 2020; 216: 153073.
22. Douglas JK, Callahan RE, Hothem ZA, et al. Genomic varia­tion as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Mol Cell Oncol 2020; 7: 1716618.
23. Unçel M, Diniz G, Akoz G, et al. Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. Eur J Breast Health. 2019; 15: 125-129.
24. Khosrowjerdi SJ, Horick NK, Clark JW, et al. Clinical and mu­tational profile of ARID1A-mutated gastrointestinal cancers: Duration of response to platinum-based chemotherapy. J Clin Oncol 2021; 39: e15611-e15611.
25. Douglas JK, Callahan RE, Hothem ZA, et al. Genomic varia­tion as a marker of response to neoadjuvant therapy in locally advanced rectal cancer. Mol Cell Oncol 2020; 7: 1716618.
26. Erfani M, Hosseini SV, Mokhtari M, et al. Altered ARID1A expression in colorectal cancer. BMC Cancer 2020; 20: 350.
27. Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferra­cin M. ARID1A in cancer: Friend or foe? Front Oncol 2023; 13: 1136248.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.